HIV‐infection during treatment of a chronic hepatitis B virus infection: implications for PrEP?

摘要

The protective effect of oral tenofovir disoproxil fumarate (TDF) with or without emtricitabine (FTC) as pre‐exposure prophylaxis (PrEP) against HIV differed significantly among clinical studies and poor PrEP‐adherence was closely associated with PrEP‐failure. Despite HIV‐infections during PrEP‐exposure the development of resistance mutations against PrEP was rarely observed so far. As PrEP is an emerging tool against HIV transmission, it is important to identify risk‐factors for PrEP‐failure and the induction of PrEP‐associated resistance mutations against antiretroviral drugs. We here present the case of a 25‐year old MSM who was successfully treated with TDF due to a chronic hepatitis B virus (HBV) infection (HBV‐DNA always